2 Information about lumasiran

Marketing authorisation indication


Lumasiran (Oxlumo, Alnylam Pharmaceuticals) is indicated 'for the treatment of primary hyperoxaluria type 1 (PH1) in all age groups'.

Dosage in the marketing authorisation



The list price of lumasiran is £61,068.98 per 94.5 mg vial (excluding VAT; Monthly Index of Medical Specialities [MIMS] online, accessed February 2023). The company has a commercial arrangement. This makes lumasiran available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)